February 08, 2005
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Macugen reimbursement terms announced
NEW YORK — The Centers for Medicare & Medicaid Services announced a reimbursement level for a recently approved drug for age-related macular degeneration.
Effective Jan. 1, Macugen (pegaptanib sodium, Eyetech/Pfizer), will be reimbursed under Medicare Part B at 106% of the average sales price, or $1,054.70 per injection, according to a press release from the drug’s marketers.
Macugen was approved by the Food and Drug Administration in December for use in the treatment of neovascular AMD. Eyetech and co-marketer Pfizer launched Macugen in the United States last month.